

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of ) Group Art Unit: 1743

Johnson et al. ) Examiner: Starsiak, J.

Serial No.: To be assigned )

Filed: February 13, 2002 (herewith) )

For: CAPILLARY ELECTROPHORESIS METHOD )  
AND APPARATUS FOR REDUCING PEAK )  
BROADENING ASSOCIATED WITH THE )  
ESTABLISHMENT OF AN ELECTRIC FIELD )

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on


EL 317622653 65  
Express Mail Number

February 13, 2002  
Date of Deposit

Liberi Guzman  
Name of Depositing Party

Liberi Guzman  
Signature of Depositing Party

JC971 U.S. PRO  
10/075404  
02/13/02


**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a) [X] accompanies a new patent application submitted herewith.

(b) [ ] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.

(c) [ ] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.

I declare that I am not aware of the existence of any other relevant information which has not been included in this statement except that which is contained in the attached Form PTO-1449. I further declare that the above information was filed prior to the earliest of the filing date or PCT national stage date of entry filing but, as far as is known to the undersigned,

prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

(f)  is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) **and** a certification as specified in 37 CFR §1.97(e), as checked below. **This document is to be considered as a petition requesting consideration of the information disclosure statement.** The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. **A duplicate of this sheet is enclosed.**

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

- Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

A copy of the item(s) in Substitute form 1449A PTO is supplied herewith:

each  none  only those listed below:


Those patent(s) or publication(s) listed in the attached Substitute form 1449A/PTO are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 09/361,485, filed July 26, 1999 and relied upon in this application for an earlier filing date under 35 USC §120.

or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date: February 13, 2002

  
Paul D. Grossman, Reg. No. 36,537  
Attorney for Applicants

**Correspondence Address**

Customer Number 22896  
Applied Biosystems Division  
PE Corporation (NY)  
850 Lincoln Centre Drive  
Foster City, CA 94404  
(650) 638-5846 (Phone)  
(650) 638-6677 (Fax)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/100,000
(Use as many sheets as necessary)		Filing Date	Feb. 1, 2000
		First Named Inventor	Bob B. Johnson
		Group Art Unit	174
		Examiner Name	J. Smith
		Attorney Docket No.	444-444

1C971 U.S. PTO  
10/075404  
02/13/02

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code (if known)				
	09	EPO	0 329 341	A2	Applied Biosystems	08-23-1989		
	10	EPO	0 362 426	A2	Applied Biosystems	08-16-1990		
	11	WO	97/24610	A1	Novartis AG	07-10-1997		
	12	WO	98/10,074	A1	The Research Foundation of State University of New York	3-12-1998		
	13	WO	01/07904	A1	The Perkin-Elmer Corp.	07-26-2000		

在這裏，我們可以說，當我們說「我」的時候，我們其實是在說「我們」，因為「我」就是「我們」的一個部分。

<sup>1</sup> unique citation designation number. See attached kinds of U.S. Patent Documents. Enter the date that issued the document by the two-letter month/4-digit year standard ST 31.<sup>2</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under A/PN Standard ST 16 if possible. Applicant is to place a checkmark in the appropriate box.

Please type a plus sign (+) inside this box →

PTO SB 08A (08-00)  
Approved for use through 10/31/2002 OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/144,901
(Use as many sheets as necessary)				Filing Date	February 1, 2001
Sheet	1	of	1	First Named Inventor	John P. Cullinan
				Group Art Unit	1748
				Examiner Name	M. S. Lask
				Attorney Docket No.	44-421

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	14	KEVIN D. ALTRIA, "Chapter 6: Optimization of Precision in Quantitative Analysis," <i>Methods in Molecular Biology</i> , Vol. 52:61-70 Capillary Electrophoresis (1996).	
	15	HUAN-TJUNG CHANG and EDWARD S. YEUNG, "Voltage Programming in Capillary Zone Electrophoresis," <i>Journal of Chromatography</i> , 632:143-155 (1993).	
	16	HIDEKO INOUE et al., "Enhanced Separation of DNA Sequencing Products by Capillary Electrophoresis Using a Stepwise Gradient of Electric Field Strength," <i>Journal of Chromatography A</i> , 602:179-184 (1993).	
	17	J.H. KNOX and K.A. McCORMACK, "Volume Expansion and Loss of Sample Due to Initial Self-Heating in Capillary Electrophoresis (CES) Systems," <i>Chromatographia</i> , Vol. 38, No. 5/6, pp. 273-282 (1994).	
	18	BILLY A. WILLIAMS and GYULA VIGH, "Effect of the Initial Potential Ramp on the Accuracy of Electrophoretic Mobilities in Capillary Electrophoresis," <i>Analytical Chemistry</i> , 67:(17)3079-3081 (1995).	

EXAMINER	APPLICANT
Signature	Considered

EXAMINER: Initials if examiner has prepared an information disclosure statement with this form. Draw a line through the examination factor if it is not applicable. Consider. Include copy of this form with next communication to applicant.

APPLICANT: Initials if applicant has prepared an information disclosure statement with this form. Draw a line through the examination factor if it is not applicable. Consider. Include copy of this form with next communication to examiner.

REMARKS: If you have any remarks concerning this form, please type or print them below. If you do not have any remarks, draw a line through the entire area.